Zdrowie i gospodarka · 14/05/2014

FDA Releases Draft Guidance on Clinical Pharmacology Data for Biosimilarity

The Food and Drug Administration (FDA) has published a draft guidance to help pharmaceutical companies develop clinical pharmacology data to demonstrate the biosimilarity of their products to established reference products, with the ultimate goal of reducing healthcare costs and increasing competition in the biologics market.